GREENBERG TRAURIG, LLP for SI GROUP CLIENT SERVICES
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Tobacco TOB
Monitored the following: -Congressional priorities on tobacco products and flavorings. -Federal and legislative action related to the marketing and advertising of tobacco products. -Federal excise taxes, including: H.R. 2786 / S. 1314, Tobacco Tax Equity Act. -Federal excise taxes and budget reconciliation negotiations, including H.R. 5376, Build Back Better Act. -FDA operations and tobacco policy on the following issues: proposed flavor restrictions, online sales bans, federal excise taxes, and tobacco product user fees. -Implementation of Family Smoking Prevention and Tobacco Control Act (P.L.113-3). -FDA action on deeming tobacco products to be subject to the Federal Food, Drug, and Cosmetic Act. -FDA's Proposed Rule, Tobacco Product Standard for Characterizing Flavors in Cigars (RIN 0910-AI28) -FDA's Advance Notice of Proposed Rulemaking, Tobacco Product Standard for Nicotine Level of Combusted Cigarettes (Docket No. FDA2017N6189) -FDA's Advance Notice of Proposed Rulemaking, Regulation of Flavors in Tobacco Products (Docket No. FDA2017N6565) -FDA's Advance Notice of Proposed Rulemaking, Regulation of Premium Cigars (Docket No. FDA2017N6107) -FDAs enforcement priorities for ENDS and other deemed products (Docket No. FDA2019D0661) -FDA's Final Rulemaking related to Cigarette Health Warning Labels (Docket No. FDA2019N3065)
| Lobbyist | Covered position, as disclosed |
|---|---|
| L ANDREW ZAUSNER | — |
Health Issues HCR
Monitored the following: -Congressional priorities on tobacco products and flavorings. -Federal and legislative action related to the marketing and advertising of tobacco products. -Federal excise taxes, including: H.R. 2786 / S. 1314, Tobacco Tax Equity Act. -Federal excise taxes and budget reconciliation negotiations, including H.R. 5376, Build Back Better Act. -FDA operations and tobacco policy on the following issues: proposed flavor restrictions, online sales bans, federal excise taxes, and tobacco product user fees. -Implementation of Family Smoking Prevention and Tobacco Control Act (P.L.113-3). -FDA action on deeming tobacco products to be subject to the Federal Food, Drug, and Cosmetic Act. -FDA's Proposed Rule, Tobacco Product Standard for Characterizing Flavors in Cigars (RIN 0910-AI28) -FDA's Advance Notice of Proposed Rulemaking, Tobacco Product Standard for Nicotine Level of Combusted Cigarettes (Docket No. FDA2017N6189) -FDA's Advance Notice of Proposed Rulemaking, Regulation of Flavors in Tobacco Products (Docket No. FDA2017N6565) -FDA's Advance Notice of Proposed Rulemaking, Regulation of Premium Cigars (Docket No. FDA2017N6107) -FDAs enforcement priorities for ENDS and other deemed products (Docket No. FDA2019D0661) -FDA's Final Rulemaking related to Cigarette Health Warning Labels (Docket No. FDA2019N3065)
| Lobbyist | Covered position, as disclosed |
|---|---|
| L ANDREW ZAUSNER | — |
Taxation/Internal Revenue Code TAX
Monitored the following: -Congressional priorities on tobacco products and flavorings. -Federal and legislative action related to the marketing and advertising of tobacco products. -Federal excise taxes, including: H.R. 2786 / S. 1314, Tobacco Tax Equity Act. -Federal excise taxes and budget reconciliation negotiations, including H.R. 5376, Build Back Better Act. -FDA operations and tobacco policy on the following issues: proposed flavor restrictions, online sales bans, federal excise taxes, and tobacco product user fees. -Implementation of Family Smoking Prevention and Tobacco Control Act (P.L.113-3). -FDA action on deeming tobacco products to be subject to the Federal Food, Drug, and Cosmetic Act. -FDA's Proposed Rule, Tobacco Product Standard for Characterizing Flavors in Cigars (RIN 0910-AI28) -FDA's Advance Notice of Proposed Rulemaking, Tobacco Product Standard for Nicotine Level of Combusted Cigarettes (Docket No. FDA2017N6189) -FDA's Advance Notice of Proposed Rulemaking, Regulation of Flavors in Tobacco Products (Docket No. FDA2017N6565) -FDA's Advance Notice of Proposed Rulemaking, Regulation of Premium Cigars (Docket No. FDA2017N6107) -FDAs enforcement priorities for ENDS and other deemed products (Docket No. FDA2019D0661) -FDA's Final Rulemaking related to Cigarette Health Warning Labels (Docket No. FDA2019N3065)
| Lobbyist | Covered position, as disclosed |
|---|---|
| L ANDREW ZAUSNER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.